HK1097908A1 - Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer - Google Patents

Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Info

Publication number
HK1097908A1
HK1097908A1 HK07104284.0A HK07104284A HK1097908A1 HK 1097908 A1 HK1097908 A1 HK 1097908A1 HK 07104284 A HK07104284 A HK 07104284A HK 1097908 A1 HK1097908 A1 HK 1097908A1
Authority
HK
Hong Kong
Prior art keywords
molecules
angiogenesis
jam
cancer
treatment
Prior art date
Application number
HK07104284.0A
Other languages
English (en)
Inventor
Beat A Imhof
Michel Aurrand-Lions
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,123 external-priority patent/US7642341B2/en
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of HK1097908A1 publication Critical patent/HK1097908A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
HK07104284.0A 2003-11-19 2007-04-24 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer HK1097908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026629A EP1533617A1 (en) 2003-11-19 2003-11-19 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US10/738,123 US7642341B2 (en) 2003-12-18 2003-12-18 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
PCT/EP2004/013247 WO2005050213A1 (en) 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
HK1097908A1 true HK1097908A1 (en) 2007-07-06

Family

ID=34621557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104284.0A HK1097908A1 (en) 2003-11-19 2007-04-24 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Country Status (19)

Country Link
US (1) US7790863B2 (ko)
EP (2) EP1533617A1 (ko)
JP (1) JP2007515159A (ko)
KR (1) KR101135834B1 (ko)
CN (1) CN1890567B (ko)
AT (1) ATE493657T1 (ko)
AU (1) AU2004291989B2 (ko)
BR (1) BRPI0415541B8 (ko)
CA (1) CA2546406C (ko)
DE (1) DE602004030819D1 (ko)
EA (1) EA009037B1 (ko)
ES (1) ES2358905T3 (ko)
HK (1) HK1097908A1 (ko)
IL (1) IL175686A (ko)
MX (1) MXPA06005523A (ko)
NO (1) NO20062793L (ko)
SG (1) SG148190A1 (ko)
WO (1) WO2005050213A1 (ko)
ZA (1) ZA200603069B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292761A1 (en) 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
JP2010504955A (ja) * 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
WO2009115615A2 (en) * 2008-03-21 2009-09-24 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
MX2011009023A (es) 2009-02-27 2011-09-28 Novartis Ag Metodos para seleccionar celulas eucarioticas que expresan una proteina heterologa.
WO2012104386A1 (en) 2011-02-02 2012-08-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonists of grasp55 for use as a medicament
WO2012160031A1 (en) * 2011-05-24 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for prognosing solid tumor outcome
US9803014B2 (en) 2012-10-24 2017-10-31 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
GB201415367D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K Methods for detecting abnormalities in haemoglobin
WO2016156400A1 (en) * 2015-03-31 2016-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
RU2599545C1 (ru) * 2015-11-06 2016-10-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1997007671A1 (fr) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Animal chimerique et procede de constitution
ATE214075T1 (de) * 1996-05-31 2002-03-15 Health Research Inc Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
EP2292761A1 (en) 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
WO2003008541A2 (en) * 2001-07-16 2003-01-30 Eli Lilly And Company Extracellular junctional adhesion molecules
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
KR100829283B1 (ko) 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
ATE527278T1 (de) 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
AU2004291989B2 (en) 2009-08-06
SG148190A1 (en) 2008-12-31
CN1890567A (zh) 2007-01-03
AU2004291989A1 (en) 2005-06-02
CA2546406C (en) 2013-04-09
KR101135834B1 (ko) 2012-04-16
IL175686A0 (en) 2006-09-05
CN1890567B (zh) 2012-12-12
CA2546406A1 (en) 2005-06-02
US20070202110A1 (en) 2007-08-30
ATE493657T1 (de) 2011-01-15
NO20062793L (no) 2006-08-18
EP1685405B1 (en) 2010-12-29
KR20060130562A (ko) 2006-12-19
EP1685405A1 (en) 2006-08-02
JP2007515159A (ja) 2007-06-14
EA009037B1 (ru) 2007-10-26
US7790863B2 (en) 2010-09-07
DE602004030819D1 (de) 2011-02-10
WO2005050213A1 (en) 2005-06-02
EP1533617A1 (en) 2005-05-25
ZA200603069B (en) 2007-09-26
ES2358905T3 (es) 2011-05-16
BRPI0415541B8 (pt) 2021-05-25
MXPA06005523A (es) 2006-12-14
IL175686A (en) 2012-02-29
BRPI0415541A (pt) 2006-12-26
EA200600995A1 (ru) 2006-10-27
BRPI0415541B1 (pt) 2018-11-27

Similar Documents

Publication Publication Date Title
HK1097908A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
EP2620450A3 (en) Anti-CTLA-4 antibody compositions
EP2305716A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
WO2008148546A3 (en) Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
WO2007006041A8 (en) Imaging and therapeutic method using monocytes
WO2003052082A3 (en) Fusion partner cells and uses thereof
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
WO2001073030A3 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
EP2548583A3 (en) Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
WO2002015846A3 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2005030266A3 (en) Optical imaging of colorectal cancer
WO2002073212A3 (en) Diagnostic screens for alzheimer's disease
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001098543A3 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
WO2002000939A3 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201119